AstraZeneca Results Presentation Deck
AstraZeneca in Breast Cancer
Ambition to eliminate breast cancer as a cause of death
established SoC
Est. epi (G7)
HER2-positive
15-20%
HR-positive
65-75%
HER2-low 1+, 2+
60%
TNBC
10-15%
HER2-low 1+, 2+
35%
gBRCAm
5% of HR-positive
15% of TNBC
Neoadjuvant
540k
Enhertu ± THP
DESTINY-Breast11
Dato-DXd +
Imfinzi
TROPION-
Breast04
Early
Low
Adjuvant
NST➜ residual disease
Enhertu
DESTINY-Breast05
Good outcomes with
current SoC
CTX → camizestrant
(+ CDK4/6i)
CAMBRIA-2
CTXAI (± CDK4/6i) 2-5 yrs
→ camizestrant
CAMBRIA-1
NST
→ residual disease
→ Dato-DXd ± Imfinzi
TROPION-Breast03
CTX → Lynparza
OlympiA
RECRURENCE
ESR1m
1st line
125k
Enhertu ± pertuzumab
DESTINY-Breast09
camizestrant + CDK4/6i
SERENA-4
Al + CDK4/6i →
camizestrant + CDK4/6i
SERENA-6
capivasertib + Faslodex + CDK4/6i
CAPItello292
PD-L1-
60%
capivasertib + paclitaxel
CAPItello290
40%
PD-L1+ Dato-DXd + Imfinzi
TROPION-Breast05
Dato-DXd
TROPION-Breast02
Metastatic
2nd line
90k
Enhertu
DESTINY-Breast03
capivasertib + Faslodex
CAPItello291
HER2-
Low
Enhertu
DESTINY-Breast06
HER2-low IHC 0-1+, 1+, 2+
Lynparza
OlympiAD
APPENDIX | Oncology tumour maps
3rd line
65k
4th line +
55k
Enhertu
DESTINY-Breast02
Dato-DXd
TROPION-Breast01
Enhertu
DESTINY-Breast04
HER2-low IHC 1+, 2+
All numbers are approximate. Illustrative settings and populations, not to scale.
1/2/3/4L = 1st/2nd/3rd/4th-line; est epi (G7) = estimated epidemiology across G7 (US, EU5, JP for drug treated patients. HER2 = human epidermal growth factor receptor 2; THP = docetaxel, trastuzumab, and pertuzumab; NST = neoadjuvant systemic
treatment; HR = hormone receptor; SoC = standard of care; CTx = chemotherapy; Al = aromatase inhibitor; CDK4/6i = cyclin-dependent kinase 4 and 6 inhibitor; yrs = years; ESR1m = estrogen receptor 1 gene mutation; Dato-DXd = datopotamab deruxtecan;
36 TNBC = triple negative breast cancer; PD-L1 = programmed cell death ligand 1; gBRCAm = germline BRCA-mutated.
Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd), Merck & Co., Inc. (Lynparza).
BView entire presentation